“The second half sales growth guidance is derisked to account for some of these items here that I consider to be a little bit more transitory that are specific in the diagnostic space, and we're going to be lapping these next year. That still leaves $1-plus billion revenue -- quarterly revenue growing high single digits throughout the rest of the year.”

In context

“lth oncology, access to GLP-1s. So the team has really done a good job laying in here a real nice pipeline of products. And as I said, we're going to start launching in a small market this year, and then we'll start rolling them out, obviously, as they become from a regulatory perspective available to us, we'll be rolling them out next year. And I think this can be a nice contributor here to our growth in this business in the next few years. Okay. Well, listen, I -- just a few comments here to close. I'm pleased with what we've accomplished in the first half. We've delivered high single-digit sales growth and double-digit EPS. We've expanded our gross margin and operating margin, which is something that we've committed to when we talked about, and we've done it by about 100 basis points. The second half sales growth guidance is derisked to account for some of these items here that I consider to be a little bit more transitory that are specific in the diagnostic space, and we're going to be lapping these next year. That still leaves $1-plus billion revenue -- quarterly revenue growing high single digits throughout the rest of the year. And on top of that, we've reaffirmed our guidance despite some of these headwinds and the impact of tariffs. So I think this is another great example of how our diversified model continues to provide that strong foundation, it's resilient and it's well positioned to deliver top-tier results. So we've got good underlying momentum here that I'm very confident will carry into next year. So with that, I'm going to wrap up. Thank you for joining us. Michael Comilla: Thank you, operator. Thank you all for your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11:00 a.m. Central Time today on Abbott's Investor Relations website at abbottinvestor.com. Thank you all for joining us today. Operator: Thank you. This concludes today's confere”